
|Videos|July 2, 2013
Episode 17 - Conclusion: Treatment Advancements and Final Remarks
Advertisement
Episodes in this series

During this segment, Patricia K. Coyle, MD, Leslie Fish, PharmD, and Gary M. Owens, MD, explain how research has expanded in the neurology field and discuss the therapeutic pipeline for multiple sclerosis (MS) with Dr Fred Lublin.
Dr Coyle discusses the potential of newly developing agents and explains that clinical trials are now testing the efficacy of these products, which is vital when considering data for future clinical guidelines.
However, Dr Owens suggests that expensive costs of treatment and the lack of clinical recommendations or guidelines can cause confusion to clinicians and challenge the future of MS.
Advertisement
Related to this article

Sustainable models require asking what a result shows, what design produced it, and whether the design was built to measure value or just produce a number.

Experts tackled CAR T access, trial equity, and overtreatment in breast cancer at an AJMC Institute for Value-Based Medicine event in San Francisco.

CMS finalized the mandatory GLOBE Model, tying Part B drug rebates to international prices in areas covering 25% of beneficiaries from Jan. 1, 2027.

AASM urges CMS to reject proposed 2027 Medicare conversion factor cuts of 1.19% to 1.68% and revise sleep testing and remote monitoring policies.

A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.

FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, coverage, and costs

CAR T-cell therapy must be treated as a complete "vein-to-vein" episode, with community practices needing to take control of cases for a period of time.
Advertisement
Advertisement
Trending on AJMC
1
Dual Agonist Survodutide Delivers Up to 13.1% Weight Loss in T2D
2
FDA Accepts Inhaled Treprostinil sNDA for IPF: 4 FAQs for Payers
3
CMS Finalizes Mandatory GLOBE Model to Test Lower Part B Drug Costs
4
Proposed Medicare Rate Cuts Draw AASM Opposition Ahead of Final Rule
5

















